ANIX 250117 2.50C (ANIX250117C2500) Stock Options, News & Quotes

0.05
-0.32-86.49%

15min DelayClose Jan 17 16:00 ET

0.22High0.05Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Nov 22, 2024 07:19

NEWS

$Anixa Biosciences (ANIX.US)$
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. ...

Bitcoin reaches new peaks. Has it just begun?

Alvinnnnnnngenius

Nov 9, 2024 19:43

We loaded heavily before the news and then we sell when the news is out , thanks for the exit liquidity fomo ppl

$Anixa Biosciences (ANIX.US)$

Jaguar8

Nov 8, 2024 12:26

NEWS

$Anixa Biosciences (ANIX.US)$
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• Data continues positive trend as additional patients are enrolled in 3 cohorts
• Vaccine was safe and well tolerated by participants in all 3 cohorts
• Protocol defined immune responses were exhibited in over 70% of patients
• A Phase 2 study evaluating the vaccine in the n...

Trytosaveabit

Nov 6, 2024 07:31

Update! Watching!

$Anixa Biosciences (ANIX.US)$ Reuters· just
Anixa Biosciences Inc - to Release Phase 1 Breast Cancer Vaccine Data on Nov 8

Jaguar8

Sep 24, 2024 07:58

NEWS

$Anixa Biosciences (ANIX.US)$
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Anixa Biosciences (NASDAQ: ANIX) has announced its strategic plan for a Phase 2 study of its breast cancer vaccine. The trial will evaluate the vaccine's efficacy in combination with chemotherapy and Keytruda in a neoadjuvant setting. This approach allows for a broader patient range and a potentially faster path to approval. The therapeutic breast cancer market is projected to reach $89.67 bil...